ClinicalTrials.gg
RecruitingNCT07335484Updated Nov 12, 2026

Aquarius Pilot Study to Evaluate the New Axonics Trial System

An interventional study of Axonics External Trial System (ETS) in Urinary Urge Incontinence (UUI), Urinary Frequency (UF) and Fecal Incontinence (FI), sponsored by Axonics, Inc.. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Axonics, Inc. (part of Boston Scientific Corporation) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 12, 20263 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 135 studies in Urinary Incontinence, Urge with a site in United States — 19 open to participants now, 26 under way, none of them phase 3. Urinary Incontinence, Urge · United States.

Planned enrollment
60th of 119
75 · median 75
Started
2026
with 4 others
No phase
72 of 135
10 open now
Primary completion
2026-11
later than 11 of 25 live
Registered
132nd of 135
by date
Lead sponsor
6 of 135
Axonics, Inc.

Among the 135 studies in Urinary Incontinence, Urge with a site in United States, this one is the 60th largest by planned enrollment of the 119 interventional ones that give a count, is one of 5 that started in 2026, is one of 72 with no phase, reaches primary completion later than 11 of the 25 other live ones, and was the 132nd registered.

Urinary Incontinence, Urge

243 studies on the registry are indexed under Urinary Incontinence, Urge; 39 are open to participants now.

Browse Urinary Incontinence, Urge studies →

Open to participants now

19 of the 135 studies in Urinary Incontinence, Urge with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Urinary Incontinence, Urge studies recruiting now, 18 (72%) set no upper age limit and 2 (8%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Urinary Incontinence, Urge with a site in United States, or all of them as a file.
02

Study summary

Evaluation of the new Axonics External Trial System (ETS-02) in patients with overactive bladder (OAB) and/or fecal incontinence (FI).

Read the detailed description

The trial system is used to determine if patients are responsive to sacral neuromodulation (SNM) prior to receiving the Axonics implantable neurostimulator (INS) which is approved for the treatment of OAB and FI. This study is evaluating the feasibility and safety of the new Axonics External Trial System (ETS-02) in patients with overactive bladder (OAB) and/or fecal incontinence (FI).

03

Conditions studied

  • Urinary Urge Incontinence (UUI)
  • Urinary Frequency (UF)
  • Fecal Incontinence (FI)
  • Overactive Bladder (OAB)

Keywords

  • Peripheral nerve evaluation
  • External trial system
  • Pilot study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Provides written prior to trial procedures
  • Primary indication of OAB (UUI/UF) or chronic FI who are considered candidates for an Axonics PNE procedure as assessed by the physician per product IFU

Exclusion criteria

Exclusion Criteria:

  • Any participant that the study Investigator deems to be a poor candidate for any reason, including, but not limited to, inability to complete a baseline bladder or bowel diary or to be compliant with study visits
  • Planned changes to current regimen of medications during the trial period that could impact bladder or bowel function
  • Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture)
  • Current symptomatic urinary tract infection (UTI)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Patients diagnosed with OAB and/or FI who are candidates for Axonics SNM (PNE) procedure

    External trial system used evaluated whether patients with OAB or FI will be responsive to sacral neuromodulation.

    Device: Axonics External Trial System (ETS)

Interventions

  • DeviceAxonics External Trial System (ETS)

    A temporary electrode wire is passed through the S3 foramen with or without fluoroscopic guidance. The wire is then connected to an external pulse generator (EPG) and is worn for a trial period ranging from 3-7 days.

    Also known as: Basic or Advanced Trial

06

What researchers measure

Primary outcomes

  1. Overall Feasibility

    Trial system success rate, defined as the proportion of participants with the Axonics ETS still attached and operable end of the trial period.

    Time frame: Day 5-7

  2. Adverse Events reporting (Safety)

    Device- or procedure-related adverse events as determined by the independent physician adjudicated (IPA).

    Time frame: Day 0-7

07

Study locations

6 of 6 sites recruiting
  • University of Birmingham, Alabama
    Birmingham, Alabama 35294, United States
    Recruiting
    • Alisha Hitt · Contact
    • Adam Baumgarten, MD · Principal investigator
  • Atrium Health - Navicent
    Macon, Georgia 31201, United States
    Recruiting
    • Jennifer Crawford, PhD · Contact
    • David Lovejoy, MD · Principal investigator
  • University of Chicago
    Chicago, Illinois 60637, United States
    Recruiting
    • Rowena Shi · Contact
    • Kimberly Kenton, MD · Principal investigator
  • Southern Urogynecology
    West Columbia, South Carolina 29169, United States
    Recruiting
    • Tina McGready · Contact
    • Andrea Pezzella, MD · Principal investigator
  • Calvary North Adelaide Hospital/Better Bladders
    North Adelaide, South Australia 5006, Australia
    Recruiting
    • Darcy Noll, MD · Contact
    • Ailsa Wilson Edwards, MD · Principal investigator
  • Epworth Freemasons Hospital
    East Melbourne, Victoria 3002, Australia
    Recruiting
    • Grace Wood · Contact
    • Sandra Elmer, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2026, 7 months after the start.

Of 77 interventional studies with no phase under Urinary Incontinence, Urge, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 13, 2026
StartActual
Apr 30, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United States)
  • University of Birmingham, Alabama · Birmingham, United States
  • Atrium Health - Navicent · Macon, United States
  • University of Chicago · Chicago, United States
across 2 updates, Oct 13, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    1 site added
    Show site
    • University of Chicago · Chicago, United States
    + 1 other change: verification date
  2. Oct 13, 2026
    2 sites added
    Show 2 added (2 United States)
    • University of Birmingham, Alabama · Birmingham, United States
    • Atrium Health - Navicent · Macon, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07335484
Lead sponsor
Axonics, Inc.
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
Apr 30, 2026
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Erum Shaikh
Contact
Erum.Shaikh@bsci.com
657.626.4310
Gita Ghadimi, OD
Contact
Gita.Ghadimi@bsci.com
949-981-4366
Ailsa Wilson Edwards, MD
principal investigator · Calvary North Adelaide Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion